Tim F. Greten

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

T. Greten, G. Wilding, J. Kolesar, 2016, Investigational New Drugs.

A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype

Henk M. W. Verheul, J. Herman, N. Ahuja, 2021, Clinical and translational science.

Peptide‐β2‐microglobulin‐major histocompatibility complex expressing cells are potent antigen‐presenting cells that can generate specific T cells

M. Manns, T. Greten, F. Korangy, 2007 .

IFN‐γ regulates survival and function of tumor‐induced CD11b+Gr‐1high myeloid derived suppressor cells by modulating the anti‐apoptotic molecule Bcl2a1

M. Manns, T. Greten, Chi A. Ma, 2014, European journal of immunology.

Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma

M. Manns, T. Greten, U. Lehmann, 2009, Immunology.

Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients

M. Manns, J. Klempnauer, S. Kubicka, 2005, British Journal of Cancer.